3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Motor Activity
4
Colorectal Neoplasms
3
Lymphoma
2
Colonic Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Obesity
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Medical Oncology
1
Malnutrition
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Glioma
1
Glioblastoma
1
Fasting
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Cancer Prevention
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Diet
×
1 year
×
Clear all
NCT07494201
2026-03-27
MIMICC
Fondazione del Piemonte per l'Oncologia
Phase NA
Recruiting
2,500 enrolled